The Latest Cardiac and Vascular News
– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the application was filed for a Type II(a) variation with the European Medicines Agency (EMA) […]
Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million upfront payment from finance agreement with HealthCare Royalty Pharmosa to receive up to $215 million in development and sales milestones for PAH and PH-ILD indications, […]
CAMZYOS is the first and only cardiac myosin inhibitor approved in the European Union Approval based on two positive Phase 3 trials, EXPLORER-HCM and VALOR-HCM, demonstrating significant benefit in patients treated with CAMZYOS versus placebo PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved CAMZYOS® (mavacamten, 2.5 mg, 5 […]
ATCOR and Datacubed Health partner on a novel remote trial solution to integratedigital vascular biomarker patient monitoring within the Datacubed Health PatientEngagement Platform IRVINE, Calif., June 26, 2023 /PRNewswire/ — ATCOR Medical, subsidiary of CardieX and developer of innovative medical devices and digital solutions to personalize healthcare and improve clinical trial patient outcomes, today announces it […]
First-of-its-Kind Data Underscore Importance of Early Use of Drug Therapy as a Primary Prevention, Especially for Those Living with Diabetes SAN DIEGO, June 24, 2023 /PRNewswire/ — Today, a new trial revealed data on the effects of bempedoic acid – a non-statin cholesterol-lowering drug – on cardiovascular outcomes, demonstrating that patients with […]
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorable safety and tolerability profile – – SHTG Phase 3 ENTRUST trial initiated in May 2023 – SAN FRANCISCO, June 24, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company […]
SHANGHAI, China and PRINCETON, N.J., June 26, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other Asian markets, today announced that CAMZYOS® (mavacamten) has received marketing approval for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) from the […]
This is the first and only single tablet combination therapy to be submitted for review in Europe for this rare, progressive disease If approved, Janssen’s comprehensive PAH portfolio has the potential to cover all guideline-recommended treatment pathways BEERSE, Belgium, June 26, 2023 (GLOBE NEWSWIRE) — The Janssen Pharmaceutical Companies of […]
Allschwil, Switzerland – June 26, 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as an oral presentation entitled “Effects of the dual endothelin antagonist aprocitentan on ambulatory blood pressure indices in […]
NEWS PROVIDED BY Anthos Therapeutics → June 26, 2023 07:00 ET Patient-Centric Survey Conducted in Collaboration with StopAfib.org and the National Blood Clot Alliance Findings Suggest “Patient-Relevant Bleeding” More Accurate Than Current Terminology, Capturing Effects on Patient Quality of Life More than Half of Patients Reported Needing to Adjust Their […]
